Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$110.77 -0.5%	$109.70	$81.20 ▼ $131.49	$26.63B	1.23	929,522 shs	697,025 shs
BPMC Blueprint Medicines	$129.46	$128.90	$73.04 ▼ $129.65	$8.36B	0.89	1.55 million shs	N/A
INSM Insmed	$132.60 +2.4%	$106.10	$60.40 ▼ $132.64	$28.03B	0.95	2.83 million shs	2.24 million shs
TEVA Teva Pharmaceutical Industries	$18.79 +6.7%	$16.72	$12.47 ▼ $22.80	$21.55B	0.62	12.19 million shs	20.15 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.09%	-1.31%	+2.19%	+12.34%	+25.72%
BPMC Blueprint Medicines	0.00%	0.00%	0.00%	+29.02%	+38.91%
INSM Insmed	+1.76%	+5.36%	+25.95%	+95.66%	+69.90%
TEVA Teva Pharmaceutical Industries	+0.23%	+2.24%	+7.98%	+3.87%	-3.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	1.6541 of 5 stars	3.4	2.0	0.0	1.9	0.8	0.0
BPMC Blueprint Medicines	0.4895 of 5 stars	2.1	0.0	0.0	0.0	0.8	0.6
INSM Insmed	4.1144 of 5 stars	2.5	4.0	4.3	3.8	1.7	0.6
TEVA Teva Pharmaceutical Industries	3.5644 of 5 stars	3.6	4.0	0.0	3.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.76	Moderate Buy	$135.80	22.60% Upside
BPMC Blueprint Medicines	2.11	Hold	$130.00	0.42% Upside
INSM Insmed	2.94	Moderate Buy	$132.57	-0.02% Downside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	31.51% Upside

Current Analyst Ratings Breakdown

Latest BPMC, BNTX, INSM, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$126.00 ➝ $144.00
8/20/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$111.00 ➝ $135.00
8/20/2025	INSM Insmed	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$138.00 ➝ $136.00
8/14/2025	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$126.00 ➝ $139.00
8/14/2025	INSM Insmed	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$121.00 ➝ $145.00
8/13/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$114.00 ➝ $142.00
8/13/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$126.00
8/13/2025	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$129.00 ➝ $148.00
8/13/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $165.00
8/12/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $140.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	8.94	N/A	N/A	$87.38 per share	1.27
BPMC Blueprint Medicines	$562.12M	14.87	N/A	N/A	$4.70 per share	27.54
INSM Insmed	$363.71M	77.06	N/A	N/A	$5.91 per share	22.44
TEVA Teva Pharmaceutical Industries	$16.54B	1.30	$3.60 per share	5.22	$5.96 per share	3.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$1.60	N/A	N/A	N/A	-12.20%	-1.84%	-1.59%	11/3/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	199.17	N/A	-27.70%	-64.60%	-17.22%	10/28/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.71	N/A	N/A	N/A	-259.82%	-195.37%	-49.49%	10/30/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	7.15	1.04	-0.95%	46.10%	7.18%	11/5/2025 (Estimated)

Latest BPMC, BNTX, INSM, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	INSM Insmed	-$1.30	-$1.70	-$0.40	-$1.70	$104.06 million	$107.42 million
8/4/2025	Q2 2025	BNTX BioNTech	-$1.41	-$1.60	-$0.19	-$1.82	$161.26 million	$306.46 million
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	8.61	8.48
BPMC Blueprint Medicines	1.01	2.80	2.75
INSM Insmed	0.45	6.68	6.33
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
BPMC Blueprint Medicines	N/A
INSM Insmed	N/A
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
BPMC Blueprint Medicines	4.21%
INSM Insmed	3.00%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.40 million	194.24 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
INSM Insmed	1,271	211.38 million	205.03 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

BPMC, BNTX, INSM, and TEVA Headlines

Recent News About These Companies

Aberdeen Group plc Acquires 286,206 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

August 21 at 4:18 AM | marketbeat.com

State of New Jersey Common Pension Fund D Buys 41,300 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

August 20 at 6:04 AM | marketbeat.com

Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters

August 20 at 3:51 AM | fool.com

Fjarde AP Fonden Fourth Swedish National Pension Fund Has $4.49 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 19 at 5:01 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by National Bank of Canada FI

August 19 at 4:15 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Lifted by Menora Mivtachim Holdings LTD.

August 18 at 7:14 AM | marketbeat.com

National Pension Service Has $25.44 Million Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 18 at 5:01 AM | marketbeat.com

Resona Asset Management Co. Ltd. Boosts Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 18 at 4:49 AM | marketbeat.com

Nuveen LLC Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 18 at 4:31 AM | marketbeat.com

Invesco Ltd. Sells 1,377,277 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 18 at 4:04 AM | marketbeat.com

Tejara Capital Ltd Makes New $2.78 Million Investment in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 17, 2025 | marketbeat.com

Lord Abbett & CO. LLC Boosts Stock Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 17, 2025 | marketbeat.com

Critical Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) & Dr. Reddy's Laboratories (NYSE:RDY)

August 17, 2025 | americanbankingnews.com

Public Sector Pension Investment Board Has $9.03 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 16, 2025 | marketbeat.com

Virtu Financial LLC Buys Shares of 24,154 Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 16, 2025 | marketbeat.com

Deutsche Bank AG Boosts Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 14, 2025 | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Acquires 53,443 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

August 13, 2025 | marketbeat.com

Senores Pharma to acquire two products of USFDA approved ANDAs from Teva Pharma USA

August 13, 2025 | medicaldialogues.inM

Teva Pharmaceutical continues gains for seven straight sessions

August 12, 2025 | msn.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by Todd Asset Management LLC

August 12, 2025 | marketbeat.com

30,900 Shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Purchased by ASR Vermogensbeheer N.V.

August 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPMC, BNTX, INSM, and TEVA Company Descriptions

BioNTech NASDAQ:BNTX

$110.77 -0.53 (-0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$111.25 +0.48 (+0.43%)

As of 04:58 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Blueprint Medicines NASDAQ:BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Insmed NASDAQ:INSM

$132.60 +3.15 (+2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$132.14 -0.46 (-0.35%)

As of 07:32 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Teva Pharmaceutical Industries NYSE:TEVA

$18.79 +1.18 (+6.71%)

Closing price 03:59 PM Eastern

Extended Trading

$18.70 -0.09 (-0.49%)

As of 07:40 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time